Mentions in press and media 16
| Date | Title | Description |
| 24.03.2026 | Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab) | Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced posi... |
| 31.10.2025 | Curve Biosciences Ignites New Era in Chronic Disease Care with $40M Funding | Curve Biosciences recently secured $40M in Series A funding. This capital fuels its Whole-Body Intelligence platform. The platform uses the proprietary Whole-Body Atlas, a vast collection of tissue samples. It powers advanced Whole-Body Blo... |
| 30.10.2025 | Curve Biosciences: $40 Million Raised To Advance Whole-Body Intelligence Platform for Chronic Disease Monitoring | Curve Biosciences, a biotechnology company pioneering Whole-Body Intelligence for proactive and personalized chronic disease care, has raised $40 million in new funding led by Luma Group, with participation from First Spark Ventures, Techas... |
| 29.10.2025 | Curve Biosciences Secures $40M to Launch Whole-Body Intelligence Platform | What You Should Know: – Curve Biosciences, the Whole-Body Intelligence™ company, today announced it has raised $40M in Series A funding led by Luma Group, with participation from First Spark Ventures, Techas Capital, Civilization Ventures, ... |
| 16.10.2025 | Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers | Roche’s Genentech said it will sell its flu pill, Xofluza, directly to certain patients at a discount in a bid to expand access to uninsured people, those with limited coverage or people whose plans don’t cover the drug. It follows similar ... |
| 09.07.2025 | Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase ... | SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and sta... |
| 15.07.2024 | 16-Year-Old Marathon Swimmer Maya Merhige Successfully Swims the English Channel and Raises More than $100,000 to Fight Cancer | 16-Year-Old Marathon Swimmer Maya Merhige Successfully Swims the English Channel and Raises More than $100,000 to Fight Cancer with Swim Across America. Berkeley, California, Resident Is Now One of the Youngest in History to Complete the Tr... |
| 11.05.2024 | Think Bioscience: Pioneering the Hunt for Drug Therapies | Think Bioscience Inc. is making waves in the biotech world with their innovative approach to developing small-molecule therapeutics that target "undruggable" proteins. With a recent $26 million seed round, including a $6 million e... |
| 07.05.2024 | Think Bioscience Raises $6M in Seed Extension | Think Bioscience, a Boulder, CO-based synthetic biology company focused on developing small-molecule therapeutics that target “undruggable” proteins, raised a $6M Seed extension funding. YK Bioventures joined existing investors, bringing to... |
| 25.10.2022 | Want To Live Longer? How Life Extension Industry Will Reboot Health, Wellness and The Economy | Do you want to live a better, healthier and longer life? Me too. |
Show more